News
ANGO
6.12
-3.32%
-0.21
Weekly Report: what happened at ANGO last week (0408-0412)?
Weekly Report · 4d ago
AngioDynamics CEO, President & Director Acquires 2.6% More Stock
AngioDynamics, Inc. CEO, President & Director, James Clemmer, recently bought US$67k worth of stock. The recent purchase is a good sign for shareholders of the company. In the last year, AngioDynamicics insiders have purchased US$6.70 worth of shares. The company didn't make a profit in the last 12 months. It's good to see an insider purchase at close to current prices. But the company does not have a high level of insider ownership. Angiodynamics owns 2.9% of Angio dynamics.
Simply Wall St · 04/12 18:51
AngioDynamics, Inc. Quarterly Report for the Period Ended February 29, 2024
Press release · 04/09 23:11
A Leaner AngioDynamics Is A High-Risk Execution-Driven Story
AngioDynamics has sold low-growth businesses, shifted to an outsourced manufacturing model, and refocused on cardiovascular and oncological care for potential growth. Recent approval of the AlphaVac F18 mechanical thrombectomy system for pulmonary embolism presents a significant opportunity in a growing market. The company's historical execution challenges raise concerns, but there is potential for a stronger, more profitable Angiodynamics.
Seeking Alpha · 04/09 20:49
Insiders Buying Zumiez And 3 Other Stocks
U.S. Stocks closed little changed on Monday. There were a few notable insider trades. Insider purchases indicate confidence in the company's prospects or that they view the stock as a bargain. AngioDynamics, Inc. And Zumiez Inc. Made recent notable insider purchases.
Benzinga · 04/09 11:29
Weekly Report: what happened at ANGO last week (0401-0405)?
Weekly Report · 04/08 09:28
AngioDynamics, Inc.'s (NASDAQ:ANGO) Shares Bounce 26% But Its Business Still Trails The Industry
AngioDynamics, Inc. Shares have gained 26% in the last month but are still down 26% over the last year. The company's price-to-sales ratio of 0.9x is still low compared to its industry peers. Its revenue growth is expected to lag the industry in the coming years. Despite this, the company's P/S is still a strong buying opportunity for investors.
Simply Wall St · 04/06 13:28
Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities
Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on AngioDynamics (ANGO – Research Report) The company has reported a significant increase in pro forma revenue. Chen is an analyst with an average return of -21.7% and a 29.59% success rate.
TipRanks · 04/05 16:25
AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment
NASDAQ · 04/05 15:43
ANGIODYNAMICS SHARES UP 9.7% AFTER OPPENHEIMER RAISES TO OUTPERFORM FROM PERFORM
Reuters · 04/05 13:30
AngioDynamics upgraded at Oppenheimer on pipeline progress
AngioDynamics upgraded at Oppenheimer on pipeline progress to Outperform from Perform. FDA approved AlphaVac F1885 medical device for pulmonary embolism. The medical device maker's shares closed 5% higher on Thursday after the upgrade. Oppensheimer issued a $12 per share target on the stock.
Seeking Alpha · 04/05 13:19
AngioDynamics Raised to Outperform From Perform by Oppenheimer
Dow Jones · 04/05 12:50
AngioDynamics Price Target Announced at $12.00/Share by Oppenheimer
Dow Jones · 04/05 12:50
Oppenheimer Upgrades AngioDynamics to Outperform, Announces $12 Price Target
Benzinga · 04/05 12:40
ATOS, SMR and EIGR are among pre market gainers
On the Move ATOS, SMR and EIGR are among pre market gainers. GCT Semiconductor Holding (GCTS) and MediaCo Holding (MDIA) are among the biggest pre market losers. Atossa Therapeutics, Inc. Provides Pemgarda 2024 net product revenue guidance.
Seeking Alpha · 04/05 12:34
ANGIODYNAMICS, INC. <ANGO.O>: OPPENHEIMER RAISES TO OUTPERFORM FROM PERFORM
Reuters · 04/05 12:18
Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential
TipRanks · 04/05 10:56
GRIN, WOOF and MRNS are among after hour movers
On the Move GRIN, WOOF and MRNS are among after hour movers. Candel Therapeutics (CADL) and Petco Health and Wellness Company (WOOF) gain. HWH International (HWH) is among the losers.
Seeking Alpha · 04/04 21:29
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. The expanded indication expands treatment options for patients with PE. The system reduces thrombus burden and improves right ventricular function, the company says.
Benzinga · 04/04 16:53
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
AngioDynamics reported earnings per share of -16 cents for the third quarter of 2024. The company reported revenue of $75.18 million. This was below the analyst estimate for earnings of -13 cents. Angiodynamics also reported results for the fourth quarter of 2015.
Investorplace · 04/04 15:53
More
Webull provides a variety of real-time ANGO stock news. You can receive the latest news about Angiodynamics through multiple platforms. This information may help you make smarter investment decisions.
About ANGO
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.